Current Advisory Committee on Immunization Practices recommendations state that all patients aged 6 months and older receive an annual influenzavaccine.
Level 2: Mid-level evidence Influenza vaccination is associated with reduced rate of death or hospitalization for influenza or pneumonia in community-dwelling elderly persons, based on observational evidence (N Engl J Med. 2007;357:1373-1381). During 713,872 person-seasons of observation from 18 cohorts of patients older than 65 years in U.S. HMOs from 1990-2000, there were 4,599 hospitalizations…
Level 2: Mid-level evidence The live attenuated flu vaccine (FluMist intranasally) appears more effective than the inactivated vaccine (Fluzone IM), based on a randomized trial of 8,352 immunocompetent children aged 6-59 months in 16 countries (N Engl J Med. 2007;356:685-696). Participants also received intranasal saline mist and IM saline injections as placebos to maintain blinding;…
In general, routine annual vaccination is recommended for all patients 6 months of age and older who have no contraindications and should be completed by the end of October.
An emerging body of research highlights plant-based vaccine manufacturing as a potential solution to risks posed by traditional egg-based manufacturing.